Topical steroid risk analysis: Differentiating between physiologic and pathologic adrenal suppression

Journal of Dermatological Treatment

Volumn 25, Issue 6, 2014, Pages 501-506

  Levin, Ethan ^a   Gupta, Rishu ^b   Butler, Daniel ^c   Chiang, Charles ^d   Koo, John Y M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Adrenal crisis; Adrenal insufficiency; Corticosteroid safety; Eczema; HPA axis; Inflammatory skin disease; Psoriasis

Indexed keywords

CLOBETASOL PROPIONATE; CORTICOSTEROID; HYDROCORTISONE;

ADRENAL SUPPRESSION; ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PRIORITY JOURNAL; RISK ASSESSMENT;

ADMINISTRATION, TOPICAL; ADRENAL INSUFFICIENCY; AGED; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; RISK ASSESSMENT;

EID: 84892152049     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2013.844314     Document Type: Article

References (50)

1. Fraser CG, Preuss FS, Bigford WD. Adrenal atrophy and irreversible shock associated with cortisone therapy. J Am Med Assoc. 1952; 149:1542-3. PubMed PMID: 14945970. Epub 1952/08/23. eng
2. Lewis L, Robinson RF, Yee J, et al. Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment. Ann Intern Med. 1953;39:116-26. PubMed PMID: 13065993. Epub 1953/07/01. eng
3. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill, 2006. p 1587-612
4. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol. 1986;115:475-84. PubMed PMID: 2946314. Epub 1986/10/01. eng
5. Haeck IM, Timmer-de Mik L, Lentjes EG, et al. Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused. Br J Dermatol. 2007;156: 979-85. PubMed PMID: 17298484. Epub 2007/02/15. eng
6. Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris - clinical efficacy and adrenal function. J Am Acad Dermatol. 1987;16:804-11. PubMed PMID: 3553247. Epub 1987/04/01. eng
7. Galderma Laboratories L. An open label, on-comparative evaluation of the adrenal suppression potential of clobetasol propionate 0.05% spray in subjects with moderate to severe plaque psoriasis: two and four week treatment. Study report D02-0204-03. Data on file. 2004
8. Eriksen K. Comparison of clobetasol propionate and betamethasone- 17,21-dipropionate with reference to adrenal suppression. Acta Derm Venereol. 1979;59:372-4. PubMed PMID: 92159. Epub 1979/ 01/01. eng
9. Gammon W, Krueger G, Van Scott E. Intermittent short courses of clobetasol propionate ointment 0.05% in the treatment of psoriasis. Curr Ther Res. 1987;42:419-27
10. Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehiclecontrolled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol. 1991;24:443-7. PubMed PMID: 2061442. Epub 1991/03/01. eng
11. Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol. 2001;2:89-92; discussion 3. PubMed PMID: 11705308. Epub 2001/11/14. eng
12. Plemons JM, Rees TD, Zachariah NY. Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus. Oral Surg Oral Med Oral Pathol. 1990;69:688-93. PubMed PMID: 2356081. Epub 1990/06/01. eng
13. Delescluse J, van der Endt JD. A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema. Cutis. 1996;57:32-8. PubMed PMID: 8646867. Epub 1996/02/01. eng
14. Cornell RC, Stoughton RB. Six-month controlled study of effect of desoximetasone and betamethasone 17-valerate on the pituitary-adrenal axis. Br J Dermatol. 1981;105:91-5. PubMed PMID: 7259982. Epub 1981/07/01. eng
15. Kelly JW, Cains GD, Rallings M, Gilmore SJ. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Australas J Dermatol. 1991;32:85-91. PubMed PMID: 1781761. Epub 1991/01/01. eng
16. Tomasini C, Castiglioni G. Plasma cortisol studies with 0.05% halometasone cream and ointment in patients with psoriasis. J Int Med Res. 1983;11:38-42. PubMed PMID: 6832467. Epub 1983/01/ 01. eng
17. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628-32. PubMed PMID: 10487457. Epub 1999/09/16. eng
18. Hebert AA, Friedlander SF, Allen DB. Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr. 2006; 149:378-82. PubMed PMID: 16939752. Epub 2006/08/31. eng
19. Lucky AW, Grote GD, Williams JL, et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis. 1997;59:151-3. PubMed PMID: 9071556. Epub 1997/03/01. eng
20. Dohil MA, Alvarez-Connelly E, Eichenfield LF. Fluocinolone acetonide 0.01% in peanut oil: safety and efficacy data in the treatment of childhood atopic dermatitis in infants as young as 3 months of age. Pediatr Dermatol. 2009;26:262-8. PubMed PMID: 19706085. Epub 2009/08/27. eng
21. Carruthers JA, August PJ, Staughton RC. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J. 1975;4:203-4. PubMed PMID: 1191997. Pubmed Central PMCID: 1674965. Epub 1975/10/25. eng
22. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643-59. PubMed PMID: 19217694. Epub 2009/02/17. eng
23. Munro DD. Topical corticosteroid therapy and its effect on the hypothalamic-pituitary-adrenal axis. Dermatologica. 1976;152: 173-80. PubMed PMID: 782954. Epub 1976/01/01. eng
24. Kelly A, Nelson K, Goodwin M, McCluggage J. Iatrogenic Cushing's syndrome. Br Med J. 1972;4:114. PubMed PMID: 5077452. Pubmed Central PMCID: 1786266. Epub 1972/10/14. eng
25. Staughton RC, August PJ. Cushing's syndrome and pituitary-adrenal suppression due to clobetasol propionate. Br Med J. 1975;2:419-21. PubMed PMID: 1125562. Pubmed Central PMCID: 1681806. Epub 1975/05/24. eng
26. Himathongkam T, Dasanabhairochana P, Pitchayayothin N, Sriphrapradang A. Florid Cushing's syndrome and hirsutism induced by desoximetasone. JAMA. 1978;239:430-1. PubMed PMID: 621843. Epub 1978/01/30. eng
27. Nathan AW, Rose GL. Fatal iatrogenic Cushing's syndrome. Lancet. 1979;1:207. PubMed PMID: 84219. Epub 1979/01/27. eng
28. Cook LJ, Freinkel RK, Zugerman C, et al. Iatrogenic hyperadrenocorticism during topical steroid therapy: assessment of systemic effects by metabolic criteria. J Am Acad Dermatol. 1982;6:1054-60. PubMed PMID: 7047591. Epub 1982/06/01. eng
29. Fairris GM, White JE, Tymms DJ, Leatherdale BA. Cushing's syndrome, topical steroids, and cling film. Lancet. 1986;2:228. PubMed PMID: 2873479. Epub 1986/07/26. eng
30. Sandoval Cruz M, Moncada B. Potent topical steroids and psoriasis. J Am Acad Dermatol. 1988;18:387. PubMed PMID: 3346427. Epub 1988/02/01. eng
31. Young CA, Williams IR, MacFarlane IA. Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate. Br J Clin Pract. 1991;45:61-2. PubMed PMID: 1931550. Epub 1991/01/01. eng
32. Ohnishi T, Suzuki T, Watanabe S, Takahashi H. Erythrodermic psoriasis associated with hyperuricemia and Iatrogenic Cushing's syndrome due to topical corticosteroid therapy. Int J Dermatol. 1996;35:379-80. PubMed PMID: 8734668. Epub 1996/05/01. eng
33. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol. 1998;38:318-21. PubMed PMID: 9486706. Epub 1998/03/05. eng
34. Abma EM, Blanken R, De Heide LJ. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med. 2002;60:148-50. PubMed PMID: 12164372. Epub 2002/08/08. eng
35. Castanedo-Cazares JP, Lopez-Lucio RH, Moncada B. Cushing syndrome following the prescription of antifungal, antibiotic, corticosteroid cream. Int J Dermatol. 2003;42:318. PubMed PMID: 12694505. Epub 2003/04/16. eng
36. Gen R, Akbay E, Sezer K. Cushing syndrome caused by topical corticosteroid: a case report. Am J Med Sci. 2007;333:173-4. PubMed PMID: 17496736. Epub 2007/05/15. eng
37. Daly J, Feiner A, Kroshinsky D. Cushing's syndrome caused by a ''skin lightening'' ointment purchased at a Brooklyn neighborhood beauty store. J Am Acad Dermatol. 2008;58:AB98
38. Pramick M, Whitmore SE. Cushing's syndrome caused by mucosal corticosteroid therapy. Int J Dermatol. 2009;48:100-1. PubMed PMID: 19126065. Epub 2009/01/08. eng
39. Durmazlar SP, Oktay B, Eren C, Eskioglu F. Cushing's syndrome caused by short-term topical glucocorticoid use for erythrodermic psoriasis and development of adrenal insufficiency after glucocorticoid withdrawal. Eur J Dermatol. 2009;19:169-70. PubMed PMID: 19106046. Epub 2008/12/25. eng
40. Tempark T, Phatarakijnirund V, Chatproedprai S, et al. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine. 2010;38:328-34. PubMed PMID: 20972726. Epub 2010/10/26. eng
41. Graber AL, Ney RL, Nicholson WE, et al. Natural history of pituitary-adrenal recovery following long-term suppression with corticosteroids. J Clin Endocrinol Metab. 1965;25:11-6. PubMed PMID: 14252277. Epub 1965/01/01. eng
42. Helfer EL, Rose LI. Corticosteroids and adrenal suppression. Characterising and avoiding the problem. Drugs. 1989;38:838-45. PubMed PMID: 2689140. Epub 1989/11/01. eng
43. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48: 181-3. PubMed PMID: 6020682. Epub 1967/02/01. eng
44. Wester R, Maibach H. Dermatopharmacokinetics in clinical dermatology. Semin Dermatol. 1983;2:81-4
45. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15; quiz 6-8. PubMed PMID: 16384751. Epub 2005/ 12/31. eng
46. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review. Drugs. 1988;36:51-61. PubMed PMID: 3076132. Epub 1988/01/01. eng
47. Ozon A, Cetinkaya S, Alikasifoglu A, et al. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab. 2007;20:219-25. PubMed PMID: 17396439. Epub 2007/04/03. eng
48. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol. 2002;3:141-7. PubMed PMID: 11978135. Epub 2002/ 04/30. eng
49. Bhutani T, Zitelli KB, Koo J. Yin-yang strategy: proposing a new, effective, repeatable, sequential therapy for psoriasis. J Drugs Dermatol. 2011;10:831-4. PubMed PMID: 21818503. Epub 2011/ 08/06. eng
50. Lebwohl M,Yoles A, Lombardi K, LouW. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39: 447-50. PubMed PMID: 9738781. Epub 1998/09/17. eng.